

6th International Conference and Exhibition on

Cell and Gene Therapy

March 27-28, 2017 Madrid, Spain

Delphi Genetics: The Staby® technology to improve bioproductions for gene therapy

Thierry Van Reeth
Delphi Genetics, Belgium

Delphi Genetics is an expert company in Genetic Engineering and Molecular Biology. The company develops innovative and alternative technologies to improve bioproductions. The main technology, called Staby® ensures the production of recombinant proteins and plasmids DNA in the absence of antibiotic resistance gene following the regulatory agencies recommendations. The Staby® technology has been approved by several big Pharma companies that confirmed the increase of production yield mainly linked to better plasmid stability and a strong reduction of bioburden of energy. The Staby® technology has been also applied to DNA immunization and/or vaccination combined to a better antigen presentation providing an alternative method to classical antibody development methods. Using these technologies, Delphi Genetics is also involved in various programs related to gene therapy. Besides the fact that the antibiotic resistance genes removal technology meets regulatory requirements for the use of naked DNA in gene therapy, it offers advantages in production of plasmid DNA involved in the development recombinant viruses (i.e AAV, adenovirus or lentivirus). The Staby® technology guarantees the stability of the plasmid DNA during the scale-up production and secondly increases the production efficiency by focusing the energy used by *E. coli* on the plasmid production. Delphi Genetics is finalizing the development of a GMP production platform for plasmid DNA.

Biography

Thierry Van Reeth completed PhD in Molecular Biology at the Free University of Brussels (ULB) in 2000. He was In-charge of the setup of the Transgenic Animal Facility of the Biopole ULB-Charleroi. He gained expertise in the field of Genetic Engineering and Mammalian Cell Culture. He started a company in the field of Transgenic Animals Services where he was In-charge of the Business and Scientific Development. He left the lab activity for three years to be part of the Business Development of a scientific recruitment company. He came back to Sciences in 2013 by joining Delphi Genetics as Scientific and Sales Manager to develop the services business of the company.

tvanreeth@delphigenetics.com

Notes: